{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:37:11Z","timestamp":1762900631367,"version":"3.41.2"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Thyrotropin (TSH)-secreting pituitary neuroendocrine tumors (PitNETs) are recognized as a rare disease. Mixed TSH PitNETs account for 20\u201325% of TSH PitNETs. This study aimed to report an extremely rare case of a mixed TSH PitNET coexisting with Graves' disease (GD) and also to review the literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 36-year-old male patient presented with elevated levels of free triiodothyronine (FT3), free thyroxine (FT4), and insulin-like growth factor 1 (IGF-1) but a non-suppressed thyroid-stimulating hormone (TSH) level. His anti-thyroglobulin antibody (TgAb), anti-thyroid peroxidase autoantibody (TPOAb), and thyrotropin receptor antibody (TRAb) tests were positive. Symptoms of palpitations, hyperhidrosis, heat intolerance, and irritability appeared 2 years before his admission. However, he showed neither any signs nor any symptoms of acromegaly. The contrast-enhanced pituitary magnetic resonance imaging (MRI) showed enlargement of the pituitary fossa, with an irregular abnormal signal mass. The patient underwent endoscopic pituitary tumor resection via a transsphenoidal approach. The postoperative pathology suggested a mixed pituitary adenoma. At 8 months after the surgery, the patient had a postoperative recurrence of hyperthyroidism, and methimazole (MMI) was then administered. The recurrence of the TSH PitNET was confirmed by the positron emission tomography-computed tomography (PET-CT), which was performed 11 months after the surgery, and treatment with lanreotide was initiated. Gradually, his levels of FT3, FT4, TSH, TPOAb, and TgAb became normal and the levels of TRAb and IGF-1 improved.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>When the circulating levels of both FT4 and FT3 were upregulated, non-suppressed TSH levels and positive thyroid antibodies were found. TSH PitNETs coexisting with GD should be carefully taken into account to avoid the potential risk of treatment-induced tumor progression.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1436400","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T06:50:21Z","timestamp":1725432621000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Mixed thyrotropin-secreting pituitary neuroendocrine tumor coexisting with Graves' disease: a case report"],"prefix":"10.3389","volume":"11","author":[{"given":"Yijing","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s40618-019-01066-x","article-title":"A 2019 update on TSH-secreting pituitary adenomas","volume":"42","author":"Beck-Peccoz","year":"2019","journal-title":"J Endocrinol Invest."},{"key":"B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13256-016-1172-4","article-title":"Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report","volume":"11","author":"Arai","year":"2017","journal-title":"J Med Case Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3389\/fendo.2020.00523","article-title":"Concurrent Graves' disease and TSH secreting pituitary adenoma presenting suppressed thyrotropin levels: a case report and review of the literature","volume":"11","author":"Fu","year":"2020","journal-title":"Front Endocrinol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1530\/acta.0.1100373","article-title":"Hyperthyroidism caused by a pituitary thyrotrophin-secreting tumour with excessive secretion of thyrotrophin-releasing hormone and subsequently followed by Graves' disease in a middle-aged woman","volume":"110","author":"Kamoi","year":"1985","journal-title":"Acta Endocrinol (Copenh)."},{"key":"B5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000355386","article-title":"d'Herbomez M, Lemaire C, Fayard A, Desailloud R, Huglo D, et al. Coexistence of thyroid-stimulating hormone-secreting pituitary adenoma and graves' hyperthyroidism","volume":"3","author":"Kamoun","year":"2014","journal-title":"Eur Thyroid J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1530\/eje.0.1510587","article-title":"Thyrotropin-producing pituitary adenoma associated with Graves' disease","volume":"151","author":"Koriyama","year":"2004","journal-title":"Eur J Endocrinol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e11047","DOI":"10.1097\/MD.0000000000011047","article-title":"Case report of recurrent atrial fibrillation induced by thyrotropin-secreting pituitary adenoma with Graves' disease","volume":"97","author":"Li","year":"2018","journal-title":"Medicine."},{"key":"B8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1752-1947-7-27","article-title":"Thyroid-stimulating hormone-secreting pituitary adenoma presenting with recurrent hyperthyroidism in post-treated Graves' disease: a case report","volume":"7","author":"Ogawa","year":"2013","journal-title":"J Med Case Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.endonu.2015.12.003","article-title":"Coexistence of thyroid hormone resistance syndrome, pituitary adenoma and Graves' disease","volume":"63","author":"Ramos-Lev\u00ed","year":"2016","journal-title":"Endocrinol Nutr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1089\/thy.2019.0470","article-title":"Diagnosing thyrotropin-secreting pituitary adenomas by short-term somatostatin analogue test","volume":"30","author":"Han","year":"2020","journal-title":"Thyroid."},{"key":"B11","doi-asserted-by":"publisher","first-page":"0223","DOI":"10.1530\/ETJ-22-0223","article-title":"Central Central hyperthyroidism combined with Graves' disease: case series and review of the literature","volume":"12","author":"Mo","year":"2023","journal-title":"Eur Thyroid J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00774-009-0050-1","article-title":"Atypical thyrotropin-secreting pituitary microadenoma revealed by severe osteoporosis in a young man","volume":"27","author":"de Rougemont","year":"2009","journal-title":"J Bone Miner Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1210\/jcem.87.8.8658","article-title":"Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up","volume":"87","author":"Dimaraki","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1210\/jc.2018-01113","volume":"103","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"817","DOI":"10.4158\/EP11324.OR","article-title":"Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated IGF-1 but normal glucose-suppressed growth hormone","volume":"18","author":"Subbarayan","year":"2012","journal-title":"Endocr Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11102-020-01064-w","article-title":"Cosecreting TSH\/GH pituitary adenomas-an 8-year experience in a single tertiary center","volume":"23","author":"Li","year":"2020","journal-title":"Pituitary."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e634","DOI":"10.1016\/j.wneu.2019.06.180","article-title":"Surgical outcome and treatment of thyrotropin-secreting pituitary tumors in a tertiary referral center","volume":"130","author":"Herguido","year":"2019","journal-title":"World Neurosurg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"dgz096","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11102-018-0921-3","article-title":"Thyrotropin-secreting pituitary adenomas: a systematic review and meta-analysis of postoperative outcomes and management","volume":"22","author":"Cossu","year":"2019","journal-title":"Pituitary."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1197244","DOI":"10.3389\/fendo.2023.1197244","article-title":"Clinical features and therapeutic outcomes of GH\/TSH cosecreting pituitary adenomas: experience of a single pituitary center","volume":"14","author":"Yu","year":"2023","journal-title":"Front Endocrinol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1210\/edrv-17-6-610","article-title":"Thyrotropin-secreting pituitary tumors","volume":"17","author":"Beck-Peccoz","year":"1996","journal-title":"Endocr Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"580264","DOI":"10.3389\/fendo.2020.580264","article-title":"Progress in the pathogenesis, diagnosis, and treatment of TSH-secreting pituitary neuroendocrine tumor","volume":"11","author":"Luo","year":"2020","journal-title":"Front Endocrinol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1436400\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T06:50:24Z","timestamp":1725432624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1436400\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":22,"alternative-id":["10.3389\/fmed.2024.1436400"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1436400","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"article-number":"1436400"}}